BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29152717)

  • 1. Anti-desmogleins autoantibodies detected by ELISA and blotting in bullous pemphigoid: what do they mean?
    Julio T; Vernal S; Turatti A; Roselino AM
    Int J Dermatol; 2018 Jan; 57(1):124-127. PubMed ID: 29152717
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-desmoglein 1 and 3 antibody, anti-BP180(NC16a) antibody, anti-BP230 antibody].
    Amagai M
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():614-7. PubMed ID: 20942145
    [No Abstract]   [Full Text] [Related]  

  • 3. Case of bullous pemphigoid coexisting with anti-desmoglein autoantibodies.
    Tie D; Yoshida T; Chinuki Y; Da X; Ishikawa N; Morita E
    J Dermatol; 2017 Jul; 44(7):822-825. PubMed ID: 28342216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrence of autoantibodies to bullous pemphigoid antigens and desmoglein 3: analysis of pathogenic and nonpathogenic antibodies.
    Ono S; Tanioka M; Tanizaki H; Fujisawa A; Koga H; Hashimoto T; Kamiya K; Aoyama Y; Iwatsuki K; Miyachi Y
    Br J Dermatol; 2013 Jun; 168(6):1357-60. PubMed ID: 23738642
    [No Abstract]   [Full Text] [Related]  

  • 5. Sensitivities and utility of non-invasive serological tests in the diagnosis of bullous pemphigoid.
    Yew YW; Tey HL
    Int J Dermatol; 2016 Sep; 55(9):e510-1. PubMed ID: 27028937
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
    Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
    J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
    [No Abstract]   [Full Text] [Related]  

  • 7. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid.
    Fujio Y; Kojima K; Hashiguchi M; Wakui M; Murata M; Amagai M; Yamagami J
    J Dermatol Sci; 2017 Mar; 85(3):208-215. PubMed ID: 28012821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-skin specific autoantibodies detected by a new immunofluorescence multiplex biochip method in patients with autoimmune bullous diseases.
    Tampoia M; Zucano A; Villalta D; Antico A; Bizzaro N
    Dermatology; 2012; 225(1):37-44. PubMed ID: 22907099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibody serum levels and intensity of pruritus in bullous pemphigoid.
    Bardazzi F; Barisani A; Magnano M; Tengattini V; La Placa M; Patrizi A; Balestri R
    Eur J Dermatol; 2016 Aug; 26(4):390-1. PubMed ID: 27210833
    [No Abstract]   [Full Text] [Related]  

  • 11. [Auto-immune bullous diseases autoantibodies (pemphigus, bullous pemphigoid): what the dermatologist must know].
    Ingen-Housz-Oro S; Hüe S; Grootenboer-Mignot S; André C
    Ann Dermatol Venereol; 2013; 140(8-9):563-70. PubMed ID: 24034645
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnostic performance of the "MESACUP anti-Skin profile TEST".
    Horváth ON; Varga R; Kaneda M; Schmidt E; Ruzicka T; Sárdy M
    Eur J Dermatol; 2016; 26(1):56-63. PubMed ID: 26771500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desmoglein1 and BP 180 ELISA indexes correlating with disease activity in a patient with coexisting pemphigus foliaceus and bullous pemphigoid.
    Ando S; Sato-Matsumura KC; Kasai M; Nemoto-Hasebe I; Hoshina D; Ohyama B; Hashimoto T; Shimuzu H
    Clin Exp Dermatol; 2009 Dec; 34(8):e995-6. PubMed ID: 20055881
    [No Abstract]   [Full Text] [Related]  

  • 14. Case of pemphigoid vegetans positive with both BP180 and BP230 in enzyme-linked immunosorbent assays.
    Nagamoto E; Fujisawa A; Jinnin M; Koga H; Ishii N; Hashimoto T; Yoshino Y
    J Dermatol; 2014 Jul; 41(7):667-8. PubMed ID: 24985550
    [No Abstract]   [Full Text] [Related]  

  • 15. Infliximab-induced bullous pemphigoid and anti-desmoglein 3 and anti-BP180 autoantibodies in a patient with ulcerative colitis.
    Tani N; Sugita K; Yanagihara S; Yamamoto O
    Eur J Dermatol; 2019 Feb; 29(1):88-90. PubMed ID: 30530408
    [No Abstract]   [Full Text] [Related]  

  • 16. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
    Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
    J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
    Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230.
    Miyashita K; Iioka H; Miyagawa F; Ishii N; Hashimoto T; Asada H
    Eur J Dermatol; 2018 Apr; 28(2):248-250. PubMed ID: 29378676
    [No Abstract]   [Full Text] [Related]  

  • 19. Enzyme-linked immunosorbent assay as a helpful diagnostic tool for pemphigus erythematosus with equivocal histologic and immunofluorescent findings.
    Desai A; Harris J; Motaparthi K
    Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
    Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
    Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.